Sponsored by
Xoft is a new device (FDA Cleared) that is used during surgery to treat the tumor bed with radiation. It might be able to replace weeks of external beam radiation with a single treatment that provides a higher dose to the area where it is needed with less damage to surrounding areas. Early results outside the USA look very good... in one randomized trial, median survival for recurrent glioblastoma treated with Xoft was 27 months, compared to 21 months in the group that got external beam radiation.